The Claim
Rapamycin is an immunosuppressant agent that exerts its immunosuppressive effect by forming a pharmacologically active complex with FKBP12, which subsequently binds to and inhibits mTOR (mammalian target of rapamycin), thereby blocking T-cell progression from the G1 to S phase of the cell cycle.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Rapamycin is a drug that calms down the immune system. It works by hooking onto a specific protein inside cells, which then locks onto and shuts down a key growth switch called mTOR, preventing immune cells called T-cells from dividing and multiplying.
See the scientific wording
Rapamycin acts as an immunosuppressant by forming a pharmacologically active complex with FKBP-12 that binds and inhibits mTOR (mammalian target of rapamycin), blocking T-cell progression from G1 to S phase of the cell cycle.
What the research says
1 studyStudy: A treasure from a barren island: the discovery of rapamycin
The study is about rapamycin (same drug), and it mentions rapamycin as an immunosuppressant and talks about mTOR, which is related to the claim. However, the available abstract is too short and unclear to confirm whether it specifically tests the exact mechanism (FKBP-12 complex formation and T-cell cycle blocking) described in the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.